Simulations Plus (SLP) Aktienübersicht
Simulations Plus, Inc. entwickelt Software für die Entdeckung und Entwicklung von Arzneimitteln zur Modellierung und Simulation sowie zur Vorhersage molekularer Eigenschaften unter Verwendung von auf künstlicher Intelligenz und maschinellem Lernen basierender Technologie weltweit. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für SLP festgestellt.
SLP Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Simulations Plus, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$18.38 |
| 52-Wochen-Hoch | US$21.01 |
| 52-Wochen-Tief | US$11.09 |
| Beta | 1.33 |
| 1 Monat Veränderung | 0.82% |
| 3 Monate Veränderung | 19.58% |
| 1 Jahr Veränderung | 33.48% |
| 3 Jahre Veränderung | -59.18% |
| 5 Jahre Veränderung | -58.07% |
| Veränderung seit IPO | 1,236.73% |
Aktuelle Nachrichten und Updates
Seeking Alpha • Jul 19
Simulations Plus: The Potential Little Spread Is Not Worth The Risk For New Money, Hold
Summary Simulations Plus reported a strong 7% revenue growth during the quarter, while its net income improved to $3.6 million. Simulation and Altaris have agreed to a buyout agreement wherein the latter will pay $18.5 per share in an all-cash deal, valuing Simulation at $375 million. The meager difference between the current stock price ($18.23) and the deal price ($18.5) reflects merger-arbitrage situation. I rate SLP a Hold. Existing holders can squeeze in more gain as the deal gets closer to completion. For Newcomers, the little upside is not enticing enough to warrant a fresh position, given potential risks associated with the impedingdeal. Read the full article on Seeking Alpha
Narrative-Update • Jun 26
SLP: Takeover Deal And AI Partnerships Will Shape Balanced Outlook
Analysts have reduced their price target for Simulations Plus to $17.25 from $22.33, reflecting updated views on the company's discount rate, revenue growth, profit margins, and future P/E assumptions. What’s in the News for Simulations Plus Altaris, LLC agreed to acquire Simulations Plus, Inc.Recent updates
Seeking Alpha • Jul 19
Simulations Plus: The Potential Little Spread Is Not Worth The Risk For New Money, Hold
Summary Simulations Plus reported a strong 7% revenue growth during the quarter, while its net income improved to $3.6 million. Simulation and Altaris have agreed to a buyout agreement wherein the latter will pay $18.5 per share in an all-cash deal, valuing Simulation at $375 million. The meager difference between the current stock price ($18.23) and the deal price ($18.5) reflects merger-arbitrage situation. I rate SLP a Hold. Existing holders can squeeze in more gain as the deal gets closer to completion. For Newcomers, the little upside is not enticing enough to warrant a fresh position, given potential risks associated with the impedingdeal. Read the full article on Seeking AlphaNarrative-Update • Jun 26
SLP: Takeover Deal And AI Partnerships Will Shape Balanced Outlook
Analysts have reduced their price target for Simulations Plus to $17.25 from $22.33, reflecting updated views on the company's discount rate, revenue growth, profit margins, and future P/E assumptions. What’s in the News for Simulations Plus Altaris, LLC agreed to acquire Simulations Plus, Inc.
Narrative-Update • Jun 06
SLP: AI Partnerships And Steady Guidance Will Shape Balanced Long Term Outlook
Analysts have reiterated a $16.00 price target for Simulations Plus, citing updated assumptions around discount rates, revenue growth, profit margins, and P/E expectations as the basis for keeping their view steady. What's in the News Simulations Plus announced a technical collaboration with NVIDIA to bring GPU acceleration and AI-assisted workflows into its PBPK, PK/PD, and QSP modeling engines, with the aim of speeding up complex drug development simulations and broadening the use of virtual population studies.Narrative-Update • May 23
SLP: AI Alliances And Moderate Guidance Will Shape Balanced Long Term Outlook
Analysts have kept their $16.00 price target for Simulations Plus unchanged, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margins, and future P/E as the key drivers behind the maintained view. What's in the News Launched a technical collaboration with NVIDIA to bring GPU acceleration and AI-assisted workflows into PBPK, PK/PD, and QSP modeling.Narrative-Update • Apr 29
SLP: AI Regulatory Collaborations And Modest Growth Outlook Will Shape Balanced Future
Analysts have maintained their $16.00 price target for Simulations Plus, noting that slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E broadly offset one another in their updated models. What's in the News Announced a funded research collaboration with Lonza Group and the U.S. Food and Drug Administration (FDA) to develop a mechanistic framework for predicting in vivo performance of amorphous solid dispersion drug products, with the aim of supporting model informed drug development and potentially reducing reliance on some clinical bioequivalence studies (Key Developments).Narrative-Update • Apr 12
SLP: AI Collaborations With Pharma And Regulators Will Drive Long-Term Upside
Analysts have reduced their price target for Simulations Plus from $20 to $16, citing updated assumptions that combine lower revenue growth expectations with a higher projected profit margin and a meaningfully lower future P/E multiple. What's in the News Simulations Plus announced collaboration programs with three large pharmaceutical companies to apply artificial intelligence within modeling workflows across the drug development lifecycle, using platforms such as GastroPlus, MonolixSuite, ADMET Predictor, and Thales (Key Developments).Analyseartikel • Feb 08
Simulations Plus, Inc.'s (NASDAQ:SLP) 26% Share Price Plunge Could Signal Some Risk
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders won't be pleased to see that the share price has had a very rough...Analyseartikel • Feb 06
Is There An Opportunity With Simulations Plus, Inc.'s (NASDAQ:SLP) 38% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$22.72 Simulations...Narrative-Update • Jan 07
SLP: Reaffirmed Guidance And AI Roadmap Will Support Further Upside
Analysts have trimmed their price target on Simulations Plus to about US$22.33 per share, reflecting a slightly higher discount rate and P/E assumptions that point to a more cautious stance on profitability. What's in the News Simulations Plus plans an Analyst and Investor Day focused on presenting its new product vision and AI solutions, highlighting where management is aiming future product development (Key Developments).Narrative-Update • Dec 14
SLP: Reinforced Revenue Outlook Will Drive Upside From Current Levels
Analysts have modestly reduced their price target on Simulations Plus to approximately 22.33 dollars from 23 dollars. This reflects a recalibration of valuation multiples, even as they acknowledge stronger revenue growth and a significantly improved profit margin outlook.Narrative-Update • Nov 29
SLP: Revenue Guidance Will Support Renewed Upside Despite Index Exclusions
Analysts have maintained their price target for Simulations Plus at $23.00. They cited stable assumptions for revenue growth, profit margins, and valuation multiples in their latest assessment.Narrative-Update • Nov 15
SLP: Revenue Forecasts Will Drive Potential Gains Despite Index Removals
Analysts have modestly adjusted their price target for Simulations Plus from $23.00 to $23.00. They cite subtle changes in assumptions around discount rate and profit margins, while maintaining steady core growth expectations.Narrative-Update • Nov 01
SLP: Upcoming Earnings Guidance And Index Changes Will Drive Renewed Optimism
Analysts have adjusted their price target for Simulations Plus to $23.00. This reflects slight updates in their financial forecasts and expectations for future growth and profitability.Analyseartikel • Oct 28
Simulations Plus, Inc. (NASDAQ:SLP) Shares Could Be 44% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$32.42 Simulations...Narrative-Update • Oct 18
Software Licensing Expansion And Integrated Services Will Ensure Future Success
Analysts have maintained the fair value estimate for Simulations Plus at $23.00. This reflects stable long-term growth expectations, even with only slight adjustments to underlying assumptions.Narrative-Update • Oct 03
Software Licensing Expansion And Integrated Services Will Ensure Future Success
Analysts have revised their price target for Simulations Plus downward from $25.33 to $23.00, citing lower projected revenue growth and profit margins as key factors in their updated outlook. What's in the News Simulations Plus was removed from the S&P Composite 1500, S&P 1000, S&P 600, and S&P 600 Health Care indices (Key Developments).Analyseartikel • Jul 31
Some Simulations Plus, Inc. (NASDAQ:SLP) Shareholders Look For Exit As Shares Take 25% Pounding
Unfortunately for some shareholders, the Simulations Plus, Inc. ( NASDAQ:SLP ) share price has dived 25% in the last...Analyseartikel • Jun 13
Simulations Plus, Inc.'s (NASDAQ:SLP) Stock Retreats 36% But Earnings Haven't Escaped The Attention Of Investors
Simulations Plus, Inc. ( NASDAQ:SLP ) shares have had a horrible month, losing 36% after a relatively good period...Analyseartikel • May 07
Are Investors Undervaluing Simulations Plus, Inc. (NASDAQ:SLP) By 28%?
Key Insights The projected fair value for Simulations Plus is US$40.15 based on 2 Stage Free Cash Flow to Equity...Seeking Alpha • Apr 16
Simulations Plus: Benefiting From FDA Modernization And AI
Summary Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation. SLP's long-term outlook remains strong due to its innovative approach and the growing adoption of AI in drug testing, making it a "Buy" for long-term investors. Read the full article on Seeking AlphaAnalyseartikel • Apr 13
Simulations Plus, Inc.'s (NASDAQ:SLP) 25% Jump Shows Its Popularity With Investors
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • Feb 08
Why Investors Shouldn't Be Surprised By Simulations Plus, Inc.'s (NASDAQ:SLP) 29% Share Price Surge
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • Jan 08
Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Analyseartikel • Nov 07
We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative
Despite posting healthy earnings, Simulations Plus, Inc.'s ( NASDAQ:SLP ) stock has been quite weak. Along with the...
Neues Narrative • Oct 27
Biosimulation Innovations And Tactical Acquisitions To Boost Drug Development Growth
Integration and expansion into new markets drive revenue growth and improved profitability through increased efficiencies and enhanced offerings.Seeking Alpha • Aug 22
Simulations Plus: Declining Margins Are A Problem
Summary Simulations Plus growth is steady, but its margins continue to decline. This has been problematic due to the company's high valuation. Simulations Plus has suggested that the demand environment is improving, but its guidance implies a meaningful deceleration in organic growth. Simulations Plus likely needs to maintain its growth rate while improving margins before its share price moves higher. The decision to cut the company's dividend suggests that an improvement in margins and cash flows could be some way off. Read the full article on Seeking AlphaSeeking Alpha • Jul 10
Simulations Plus: Steady Growth, But What About The Margins?
Summary Simulations Plus, Inc. has seen stagnant stock trading despite impressive growth in the biosimulation market. Recent margin pressure and M&A activity raise concerns about management's ability to deliver. Acquisition of Pro-ficiency Holdings doubles the addressable market, but uncertainty remains about growth and margins amidst a demanding valuation. Read the full article on Seeking AlphaAktionärsrenditen
| SLP | US Healthcare Services | US Markt | |
|---|---|---|---|
| 7D | 0.4% | -0.3% | -2.1% |
| 1Y | 33.5% | -19.1% | 18.8% |
Rendite im Vergleich zur Industrie: SLP übertraf die Branche US Healthcare Services , die im vergangenen Jahr eine Rendite von -19.1 erzielte.
Rendite vs. Markt: SLP übertraf den Markt US, der im vergangenen Jahr eine Rendite von 18.8 erzielte.
Preisvolatilität
| SLP volatility | |
|---|---|
| SLP Average Weekly Movement | 5.0% |
| Healthcare Services Industry Average Movement | 10.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: SLP hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: SLPDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1996 | 213 | Shawn O'Connor | www.simulations-plus.com |
Simulations Plus, Inc. entwickelt Software für die Entdeckung und Entwicklung von Arzneimitteln zur Modellierung und Simulation sowie zur Vorhersage molekularer Eigenschaften unter Verwendung von auf künstlicher Intelligenz und maschinellem Lernen basierender Technologie weltweit. Das Unternehmen ist in den Segmenten Software und Dienstleistungen tätig. Das Unternehmen bietet GastroPlus, das die Absorption, Biopharmazie, Pharmakokinetik und Pharmakodynamik bei Mensch und Tier vorhersagt, sowie die Simulationsprodukte DDDPlus und MembranePlus.
Simulations Plus, Inc.'s Grundlagenzusammenfassung
| SLP grundlegende Statistiken | |
|---|---|
| Marktanteil | US$371.53m |
| Gewinn(TTM) | US$8.11m |
| Umsatz(TTM) | US$82.06m |
45.9x
Kurs-Gewinn-Verhältnis 4.5x
Kurs-Umsatz-VerhältnisIst SLP zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| SLP Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$82.06m |
| Kosten der Einnahmen | US$30.05m |
| Bruttogewinn | US$52.01m |
| Sonstige Ausgaben | US$43.90m |
| Gewinn | US$8.11m |
Zuletzt gemeldete Gewinne
May 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 0.40 |
| Bruttomarge | 63.38% |
| Nettogewinnspanne | 9.88% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich SLP auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/20 15:06 |
| Aktienkurs zum Tagesende | 2026/08/20 00:00 |
| Gewinne | 2026/05/31 |
| Jährliche Einnahmen | 2025/08/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Simulations Plus, Inc. wird von 10 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Larsen | BTIG |
| Dane Leone | CGS International |
| Constantine Davides | Citizens JMP Securities, LLC |